Biomind Labs Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alejandro Antalich
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 701 West Georgia Street, Suite 515 Vancouver BC Canada V7Y 1C6
- IPO Date
- Jul 27, 2021
- Website
- biomindlabs.com
- Similar Companies
- Business
- Biomind Labs Inc. Biomind Labs Inc. (BMNDF), a biotechnology research and development company founded in 2019 and headquartered in Toronto, Canada, with operations in Canelones, Uruguay, focuses on transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for psychiatric and neurological conditions. The company develops a diversified pipeline of fast-acting, controlled-release formulations derived from psychedelic molecules such as N,N-dimethyltryptamine (DMT), 5-MeO-DMT, and mescaline, targeting specific therapeutic indications including treatment-resistant depression (BMND01 in Phase II), fibromyalgia (BMND02 in evaluation), addictive disorders (BMND03 in pre-clinical), chronic pain (BMND05 in evaluation), morbid obesity (BMND06 in Phase I), major depressive disorder (BMND07 in evaluation), Alzheimer's disease-related depression and anxiety (BMND08 in Phase II), and Parkinson's disease (BMND09 in Phase I); it emphasizes tailored drug delivery, personalized medicine, and sustainable production to address biochemical and neurological disease drivers. Recent developments include the announcement of positive Phase II results for BMND08 in treating depression and anxiety in Alzheimer's patients in March 2024, the unveiling of BMND06 as a novel obesity treatment targeting neurological pathways in July 2024, the revocation of a cease-trade order in November 2025 following the filing of delayed 2024 audited financial statements, and an ongoing robust intellectual property portfolio with 19 patent applications across USPTO, PCT, and EPO channels.
Biomind Labs Applauds Landmark Executive Order Accelerating Psychedelic Research and Access in The United States
Biomind Labs Announces CAD $2.52 Million Private Placement Financing
Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood
Biomind Labs Announces Revocation of Cease Trade Order
Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board
Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways
Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer's Disease
Biomind Labs Provides Corporate Update
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications